174 CHAPTER 8 115. Atarashi H, Uchiyama S, Inoue H, Kitazono T, Yamashita T, Shimizu W, et al. Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: Sub-analysis of the EXPAND study. Heart Vessels. 2021;36(9):1410–20. 116. Briasoulis A, Gao Y, Inampudi C, Alvarez P, Asleh R, Chrischilles E, et al. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses. BMC Cardiovasc Disord. 2020;20(1):42. 117. Cho MS, Yun JE, Park JJ, Kim YJ, Lee J, Kim H, et al. Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing. Am J Cardiol. 2020;125(9):1332–8. 118. de Groot JR, Weiss TW, Kelly P, Monteiro P, Deharo JC, de Asmundis C, et al. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. Eur Heart J Cardiovasc Pharmacother. 2021;7(FI1):f30-9. 119. Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, et al. Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings. J Thromb Thrombolysis. 2019;48(4):653– 60. 120. Inoue H, Uchiyama S, Atarashi H, Okumura K, Koretsune Y, Yasaka M, et al. Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance. J Cardiol. 2019;73(6):507–14. 121.Inoue H, Umeyama M, Yamada T, Hashimoto H, Komoto A, Yasaka M. Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study. J Cardiol. 2020;75(2):208–15. 122.Kobayashi T, Sotomi Y, Hirata A, Sakata Y, Hirayama A, Higuchi Y. Impact of direct oral anticoagulant off-label reduced dose in combination with antiplatelet agents on clinical outcome: Propensity score-matching analysis from the DIRECT real-world non-valvular atrial fibrillation registry. Circ Rep. 2020;2(6):289–96. 123. Lee KH, Park HW, Lee N, Hyun DY, Won J, Oh SS, et al. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation. Europace. 2017;19(suppl_4):iv1–9. 124.Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GY. Optimal rivaroxaban dose in Asian patients with atrial fibrillation and normal or mildly impaired renal function. Stroke. 2019;50(5):1140–8. 125. Lee SR, Choi EK, Park SH, Jung JH, Han KD, Oh S, et al. Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):415–23. 126. Murata N, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, et al. Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA AF registry. Circ J. 2019;83(4):727–35. 127. Ohno J, Sotomi Y, Hirata A, Sakata Y, Hirayama A, Higuchi Y. Dose of direct oral anticoagulants and adverse outcomes in Asia. Am J Cardiol. 2021;139:50–6. 128.Salameh M, Gronich N, Stein N, Kotler A, Rennert G, Auriel E, et al. Stroke and bleeding risks in patients with atrial fibrillation treated with reduced apixaban dose: A real-life study. Clin Pharmacol Ther. 2020;108(6):1265–73. 129.Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, et al. Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: Results from ORBITAF II (the outcomes registry for better informed treatment of atrial fibrillation II). J Am Heart Assoc. 2018;7(4):e007633.
RkJQdWJsaXNoZXIy MTk4NDMw